Pituitary-dependent and adrenal tumor hyperadrenocorticism: which treatment is best? by Reusch, C E
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Pituitary-dependent and adrenal tumor hyperadrenocorticism: which
treatment is best?
Reusch, C E
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81754
Originally published at:
Reusch, C E (2013). Pituitary-dependent and adrenal tumor hyperadrenocorticism: which treatment is
best? In: Annual meeting of the Portuguese Veterinary Small Animal Association, Lisbon, Portugal, 11
May 2013 - 12 May 2013.
Pituitary-dependent and adrenal tumor hyperadrenocorticism: which treatment is best? 
 
 
Claudia E. Reusch 
Prof. Dr., Dipl ECVIM-CA 
Clinic for Small Animal Internal Medicine, University of Zurich, Switzerland 
 
 
The method of treatment must be carefully chosen based on the cause (PDH or AT) of 
disease, age and condition of the patient and presence of concomitant disease. Cost and 
availability of treatment methods as well as frequency of follow-up evaluations are also 
important considerations. Before treatment options can be discussed with the owner the form 
of hyperadrenocorticism (HAC) should be known. Adrenal ultrasonography and measurement 
of endogenous ACTH are the diagnostic tools which enable discrimination between PDH and 
AT in the majority of dogs. In dogs in which PDH is confirmed we highly recommend 
evaluation of the size of the pituitary mass by means of CT or MRI, in particular in dogs in 
which the low-dose dexamethasone test showed so-called dexamethasone resistance. 10 – 
15% of dogs with PDH have a large pituitary mass; those dogs are in danger to develop 
neurological signs additionally to the signs of cortisol excess. If the mass is in fact large 
(approximately > 8 mm in height) in a particular patient we recommend to perform radiation 
therapy. However, the owner needs to understand that radiation therapy aims to reduce tumor 
size and improvement or prevention of neurological signs, it usually does not lead to a 
disappearance of the endocrine signs, such as polyuria/polydipsia, polyphagia, hair loss, 
panting. Most masses shrink in size considerably within days to weeks. Three to four weeks 
after the end of radiation therapy the patient is re-evaluated in particular with regard to 
clinical signs of cortisol excess, e.g. pu/pd, polyphagia, panting. If they are still present 
(which is usually the case) we start with medical treatment. In dogs with a small pituitary 
mass we discuss that there are two treatment options: medical treatment and surgery. During 
the last decade transsphenoidal pituitary surgery has been established as a valuable treatment 
option for dogs with PDH. Most dogs with PDH can be “cured” by this approach however, 
lifelong supplementation with thyroxine and glucocorticoids is usually needed. Pituitary 
surgery is possible only in a few specialized veterinary institutions and requires a team 
approach, involving a neurosurgeon, an endocrinologist and a radiologist.
 
 Transsphenoidal 
hypophysectomy has the potential to become the treatment of choice for dogs (and cats) with 
PDH and owners are often extremely satisfied with the outcome.  
Vetoryl (trilostane) is the only drug licensed for the treatment of canine HAC. The drug has 
been evaluated in many clinical studies and has been found to be efficacious and usually well 
tolerated. In 80 – 85% of dogs with HAC clinical signs such as pu/pd, panting and lethargy 
disappear or improve substantially within a few weeks. Hair coat abnormalities may need 
several months for improvement, some dogs may have transient worsening of their 
dermatologic problems before clinical improvement. Polyphagia often persists or decreases 
only marginally. Treatment protocols vary between institutions. In Zurich we currently start 
therapy with 2 mg/kg Vetoryl SID, administered in the morning with food. Re-evaluations are 
scheduled after 2, 4, 8, 12 – 16 weeks and then every 6 months. The ACTH stimulation test is 
used to monitor treatment and is performed 2 – 3 hours after the application of the drug. A 
post ACTH cortisol concentration between 2 – 5 µg/dl (55 – 135 mmol/l) is considered an 
appropriate response. If clinical improvement is unsatisfactory after approximately 12 weeks 
we discuss BID instead of SID application with the owner. Since we do not use more than 60 
mg/dog/day as initial dosage we have not seen any serious side effects such as adrenal 
necrosis.  
Surgical removal is the treatment of choice for adrenal tumors, providing that there is no 
wide-spread tumor invasion and the dog is not debilitated. Adrenalectomy is technically 
challenging and should be performed by a skilled surgeon. Approximately 30 - 50 per cent of 
patients develop severe postoperative complications, which include hemorrhage pancreatitis, 
pneumonia, pulmonary thromboembolism, acute renal failure, sepsis and 
hypoadrenocorticism due to insufficient steroid levels. It is not known whether dogs with AT 
that undergo long-term medical treatment before adrenalectomy, have fewer postoperative 
complications and higher survival rates. Autonomous cortisol secretion results in atrophy of 
the cells of the zona fasciculata and zona reticularis, and in a few dogs the aldosterone-
producing cells of the zona glomerulosa. Thus glucocorticoid substitution intraoperatively and 
postoperatively is necessary. Mineralocorticoid treatment is instituted when required. 
Intravenous fluids (0.9% NaCl or Ringer`s solution) should be administered at a maintenance 
rate at the start of anaesthesia, during surgery and the postoperative period. When the tumor is 
located, dexamethasone should be given at a dosage of 0.1 mg/kg over a 6-hour period. The 
dose should be repeated until oral medication can be started. An alternative to dexamethasone 
is hydrocortisone, which can be given at a dosage of 4 to 5 mg/kg, intravenously, during 
surgery, and then at 1 mg/kg, intravenously, every 6 hours until oral medication is started. 
Prednisolone is then administered orally approximately as follows: 1 mg/kg BID for 2 to 3 
days, 0.5 mg/kg BID for 2 to 3 days, 0.25 mg/kg BID for 3 weeks, 0.25 mg/kg SID for 3 
weeks, 0.25 mg/kg every other day for 3 weeks, and then 0.25 mg/kg every 3 days. 
Prednisolone can usually be discontinued after 2 to 3 months. The ACTH stimulation test is 
helpful for evaluation of adrenal function.  
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